Measuring operator radiation exposure during image-guided robotic bronchoscopy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm observational study designed to record bronchoscopist radiation dose during standard-of-care image-guided robotic-assisted bronchoscopy (RAB) for sampling of a single pulmonary parenchymal lesion. Each participating site enrolls one operator who wears radiation dosimeters during routine RAB procedures, and no changes to patient care are required. Patients under 18, pregnant patients, cases sampling more than one lesion, localization-only procedures, and therapeutic procedures are excluded. Collected data will describe operator exposure patterns across procedures and settings to inform safety practices.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Operator performing image-guided RAB on adult patients (age ≥18 years old)
* A single participating operator per study site
* Image-guided RAB procedure is planned for standard of care diagnostic sampling of a single parenchymal lung lesion at participating sites

Exclusion Criteria:

* Operator refusal to participate
* Image-guided RAB procedure performed on:

  * Patients age \<18 years old
  * Pregnant women
  * Patients undergoing standard of care robotic assisted bronchoscopy with plan to sample \>1 pulmonary parenchymal lesion
  * Patients undergoing standard of care robotic assisted bronchoscopy for lesion localization (injection of dye/marker or fiducial marker deployment)
  * Patients undergoing standard of care robotic assisted bronchoscopy for a therapeutic intervention

Where it's running

• Orlando Health (Data Collection Only)
  Orlando, Florida, United States Recruiting
• Emory University (Data Collection Only)
  Atlanta, Georgia, United States Recruiting
• Mayo Clinic (Data Collection Only)
  Rochester, Minnesota, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activites)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Or Kalchiem-Dekel, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Or Kalchiem-Dekel, MD
• Email: kalchieo@mskcc.org
• Phone: 212-639-5061

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Retifanlimab after chemoradiation for anal cancer

  This study tests whether retifanlimab can help people with anal squamous cell carcinoma who have completed chemoradiation and still have residual disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07927998

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• Graft-versus-host disease after stem cell transplant: testing LBP-MARCO with ruxolitinib

  We are testing whether combining LBP-MARCO with ruxolitinib is safe for adults with GVHD after a stem cell transplant.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07913672

• 68Ga-FAPI PET/MRI imaging to see if it can track breast cancer response to chemotherapy

  This study tests whether a new imaging scan, 68Ga-FAPI PET/MRI, can show how well invasive breast cancer responds to neoadjuvant chemotherapy in adults.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07899892

• Can we skip radiation after lumpectomy for low-risk HER2-positive breast cancer?

  This study tests whether patients who had breast-conserving surgery and low-risk HER2-positive breast cancer can safely skip radiation therapy while receiving HER2-targeted treatment.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895511

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.